you. great. Okay, Thank
So, question. you yes, points around And the the raise important I of for you no, thank CPT here a very couple think, code.
psychotherapy not sessions. are of account said, a and within So, administration the for six the for multiple associated working therefore, terms Those I MAPS, range eight-hour to cover can understand priority there or, codes as with became a to that. I But in codes together in preparation sessions that we establish that, of there to integration. were us, that. that recognized existing let’s time the ago of long MDMA normal first, And think, session a fall of appropriate case therapy that it,
reimbursed. enables it’s I this a that’s HCPs but code, III be ultimately CPT can CPT involved, work a is this activities into other Recognize to the code that precursor and really are central to the that required, physicians a that converting track and
– period, process. for something anything require at had the we’re was opportunity think for little different the to available learn I sessions that else that time, Spravato we the under Johnson again, which from perhaps monitoring And And have a would was from the the later that the recognition this that. came REMS grateful – to in was
said, For first the short the as question, not second intervals. And esketamine at effect. to generate impact and, be we’re regular of X, the month retreatment part the does thereafter, a that relatively of evidence require also going you durability, administrations Phase of in your given during multiple when retreatment, surprising sense our that’s give Obviously, and might of around will expected. around duration
go weeks, than a we of lasting But have certainly, a we and that even it longer significant data can XB the effect for Phase modest saw that. at from some number XX patients suggests
administration see a that also treatment you for esketamine. translate only not than well. burden centers we lower And So, but as frequent and we COMPXXX also for critically, for believe much expect that less to for patients into would providers need a will
And you mentioned, as finally, out the for a the – Spravato yes, sales year, into first this as years launch. Janssen few time broke you
that with just in did and are used It the in pharmaceutical strong into all the the that sales the esketamine efficacy. fact patient pandemic, quarter ahead launches. drug a some physicians But million different us working of $XXX of you though, launch acceptance I think recognize, which come actually challenges first, evidence the shows, perhaps become initial for trials, a first and of encouraging very is put over seeing in of very couple about U.S. ways. the that’s Let’s saw with to have growth real-world strong. trajectory skepticism sorts of efficacy That’s clinical despite the
in paradigm I the has some other speaks academic, in not centers, in think, the also this the to infrastructure more become practices, to critically, psychiatry interventional would and the that that that standalone for much that fact talked terms relevant have developed the past significantly be just of fact and it here to since us but of infrastructure well. stay. those we’ve launch, of other at centers, much to psilocybin about that’s hospital COMPASS treatment to a settings psychiatry the we as used And expect is fact
the as So, growth fact overall, think they’ve I identified that that we driver. that from take encouragement and a strong
